Skip to content Skip to footer
Subscribe Now
AstraZeneca and Insitro
NEWS

AstraZeneca and insitro Enter ~$1.5B AI R&D Collaboration for Novel Targets in MASH and Cardiomyopathies

Shots: AstraZeneca has entered a worldwide exclusive research collaboration & licensing agreement with insitro to discover novel targets and advance therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) and cardiomyopathies using AI As per the deal, insitro will receive $40M upfront and is eligible for up to ~$1.46B in discovery, development & commercial milestones, plus single-digit royalties…
2 hours ago

Read more

Revolution Medicines
NEWS

Revolution Medicines Receives the CHMP’s Positive Opinion for Rasonque (Daraxonrasib) to Treat Previously Treated Metastatic Pancreatic Adenocarcinoma

Shots: The EMA’s CHMP has adopted a positive opinion recommending marketing authorization of Revolution Medicines’ Rasonque (daraxonrasib) once-daily oral tablets as monotherapy for adults with metastatic pancreatic adenocarcinoma (PDAC) who have received ≥1 prior systemic therapy; if approved by the EC, it would be the first broad RAS-targeted treatment option in the EU for these…
2 hours ago

Read more

Labcorp & OPKO Health
NEWS

Labcorp to Acquire Select Assets of OPKO Health’s BioReference Health for $722M

Shots: Labcorp has entered into an agreement with OPKO Health to acquire select assets of OPKO’s wholly owned subsidiary BioReference Health, incl. its laboratory testing businesses focused on clinical & women’s health testing services, urology, corrections and certain operational assets, incl. >80 additional patient service centers As per the deal, Labcorp will pay $722M in…
2 hours ago

Read more

Osivax
NEWS

Osivax Reports P-IIb (Asuniva) Trial Results of OVX836 for Seasonal Influenza and Advances Combination Vaccine Strategy

Shots: Osivax reported that the P-IIb (Asuniva) field efficacy trial of OVX836 (480 µg) vs PBO in 2,850 healthy adults aged 18–59yrs. in Europe did not meet its pre-specified 1EP of 50% vaccine efficacy (VE), with a VE point estimate of 24% (not statistically significant) 2EPs showed VE point estimates of 28% (CDC-defined influenza-like illness),…
2 hours ago

Read more

GE HealthCare
NEWS

GE HealthCare’s MINItrace Magni Cyclotron Receives CE Mark and Adds Copper-64 to PETtrace Solid Target Platform

Shots: GE HealthCare’s MINItrace Magni cyclotron has received CE Mark; the compact, self-shielded system with automated operation is designed to produce Fluorine-18, Carbon-11, Oxygen-15 & Nitrogen-13 radioisotopes for PET tracers, supporting local, in-house radioisotope production MINItrace Magni features an intuitive user interface, a three-click workflow and automated features incl. auto-tuning, which prepares the cyclotron &…
2 hours ago

Read more